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ess: chage@iupui.edu (Summary Antigen detection is a useful adjunct for the diagnosis of histoplasmosis.
The purpose of this study was to evaluate antigen detection in bronchoalveolar
lavage (BAL) ﬂuid using an improved second-generation Histoplasma antigen assay.
Antigen was detected in 16 of 19 (84%) cases of histoplasmosis and 5 of 6 (83.3%)
blastomycosis cases using the second-generation assay vs. 13 of 19 (68%) and 4 of 6
(66.7%), respectively, in the original assay. Ten-fold concentration permitted
detection of antigen in an additional case of histoplasmosis and another with
blastomycosis, for an overall sensitivity of 23 of 25 (92.0%). Speciﬁcity was 98.2% in
both assays in controls with other pulmonary infections. These ﬁndings support the
diagnostic utility of the second-generation assay in patients with pulmonary
histoplasmosis and blastomycosis.
& 2006 Elsevier Ltd. All rights reserved.Elsevier Ltd. All rights reserv
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Antigen detection has proven useful in the diag-
nosis of histoplasmosis.1 In disseminated disease,
antigen was detected in the urine in 92% and the
serum in 85% of patients.2 Histoplasma antigen can
be detected in the urine in 80% of patients withed.
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subacute pulmonary involvement, and 14% with
chronic pulmonary involvement.3 Those studies
used the originally described radioimmunoassay
method.1 Subsequently detection of antigen in
bronchoalveolar lavage (BAL) ﬂuid in 70% of speci-
mens from patients with AIDS and disseminated
histoplasmosis was reported.4 The Histoplasma
antigen test was adapted to an enzyme immunoas-
say format in 1997,5 and recently modiﬁed to
improve sensitivity and speciﬁcity. In the new
second-generation Histoplasma antigen assay, anti-
gen was detected in the urine in 24 of 33 (73%)
cases with false negative results using the original
method (Wheat, Transpl Inf Dis 2006, in press).
Cytology or histopathology on BAL or transbron-
chial lung biopsy specimens has limited sensitivity for
diagnosis of histoplasmosis.2 While histopathology
using Gomori methenamine silver and Giemsa stain
was positive in 70% of BAL specimens in patients with
AIDS and disseminated histoplasmosis with pulmon-
ary inﬁltrates, the sensitivity of these methods in
patients with the other histoplasmosis pulmonary
syndromes is expected to be lower. For example, in
the self-limited, subacute pulmonary histoplasmosis
cultures of bronchial washings were positive in none
of 35 patients, sputum in 7 of 72 (10%) and lung
biopsy in 3 of 14 (21%).6 Since culture is more
sensitive than histopathology in histoplasmosis,2
diagnosis by cytology or histopathology is likely to
be even lower than 10%. Although culture is more
sensitive in chronic pulmonary histoplasmosis, posi-
tive in half to three-quarters of cases,2,6,7 organisms
were seen by fungal stain of respiratory specimens in
only one of six (17%) patients in one review.2 Fungal
stains of respiratory specimens are positive in less
than 20% of cases of the ‘‘epidemic’’ form of acute
pulmonary histoplasmosis following high inoculum
exposure (Wheat, Expert Opin Biol Ther, 2006, in
press). Furthermore, fungal stains may be falsely
positive due to infection or colonization with yeast
morphologically similar to Histoplasma capsulatum.
These limitations of antigen testing of urine and
serum, and cytology and histopathology of respira-
tory specimens for rapid diagnosis of the pulmonary
histoplasmosis syndromes, and the improvement in
sensitivity of the second generation Histoplasma
antigen assay forms the basis for evaluation of BAL
specimens in the new assay.
The following is an illustrative case where
Histoplasma antigen detection and analysis of the
BAL provided a rapid diagnosis when the urine
antigen was borderline positive and the serum
antigen was negative:
A 61-year-old woman had undergone an ortho-
topic liver transplant in 1993 for primary biliarycirrhosis. Six years later she developed pulmonary
histoplasmosis, was successfully treated, and
placed on maintenance ﬂuconazole therapy until
February 2001. She developed lung inﬁltrates
associated with a chronic pulmonary illness from
November 2001 until March 2002. The Histoplasma
urine antigen was weakly positive at 2.4 units and
the serum antigen was negative. A bronchoscopy
with BAL was performed. The Histoplasma antigen
was strongly positive when performed on the BAL
ﬂuid (11.15 units using the old assay and 52.2 units
when retested using the new assay). The fungal
stains of the BAL were interpreted as small budding
yeast, not speciﬁcally noted as resembling H.
capsulatum. Three weeks later the BAL cultures
grew H. capsulatum, conﬁrming the diagnosis of
pulmonary histoplasmosis.
Antigen detection in the BAL ﬂuid assisted in the
rapid diagnosis of histoplasmosis in this compli-
cated patient.Methods
Patient specimens
Specimens were obtained from the following
sources: (1) specimens submitted to the Indiana
University Medical Center for microbiological test-
ing, (2) specimens submitted to the Clinical
Bronchoalveolar Lavage Laboratory at the Indiana
University Medical Center for analysis of immuno-
logic lung disease, or (3) specimens submitted to
MiraVista Diagnostics for antigen testing. As the
specimens were obtained from three different
laboratories, procedures for processing the speci-
men storage differed. Specimens were stored
refrigerated or frozen for variable time periods
prior to testing. In order to evaluate the utility of a
concentration step, 16 specimens were concen-
trated ten-fold using 5000MWCO Amicon Ultra
Centrifugal Filter Devices (Millipore).
Medical records were reviewed to conﬁrm the
ﬁnal diagnosis of fungal infection for the specimens
obtained at Indiana University Medical Center. For
specimens from patients with histoplasmosis and
blastomycosis submitted to MiraVista Diagnostics,
minimal clinical information was available, namely
the basis for diagnosis (positive culture, serology,
histopathology or antigen). Cases were classiﬁed as
histoplasmosis or blastomycosis if conﬁrmed by
microbiological or histopathology. Control speci-
mens included 16 with other fungal infections and
38 with non-fungal infections. The other fungal
infections included cases with positive histopathol-
ogy or culture for Cryptococcus neoformans and
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Figure 1 BAL ﬂuid specimens (n ¼ 25) were tested using
the original and the second-generation Histoplasma
antigen test simultaneously. Nineteen samples were from
cases of conﬁrmed histoplasmosis (circles). The remain-
ing 6 were from cases of blastomycosis (squares). The
second-generation test yielded a higher sensitivity than
the original assay (P ¼ 0:125).
Diagnosis of histoplasmosis & blastomycosis by antigen in BAL 45Pneumocystis carinii, and specimens containing
elevated levels of Aspergillus galactomannan in
the Platelia A. galactomannan assay.8 Non-fungal
infection controls included specimens from pa-
tients with positive culture for mycobacteria,
bacteria, and fungal organisms that clinically
represented colonization (Aspergillus, Candida)
rather than true infection.
Histoplasma antigen detection assay
The ‘‘original’’ assay was a sandwich enzyme
immunoassay (EIA).1 Brieﬂy, the assay uses micro-
plates coated with rabbit IgG antibodies to
H. capsulatum. Antigen present in body ﬂuids
attaches to the solid phase capture antibody, and
is detected with an enzyme labeled detector
antibody, creating a color reaction that is measured
using a microplate reader. The new second-genera-
tion assay employs a biotinylated detector antibody
that has been chemically modiﬁed to improve
sensitivity and speciﬁcity (Wheat, Transpl Inf Dis,
2006, in press). In both assays, results were
classiﬁed as positive or negative by comparison to
a negative control specimen5; and result greater
than twice the optical density of the negative
control cutoff were considered positive. The
optical density of the patient specimen was divided
by the cutoff optical density, and results were
reported as assay units, with results above one unit
being positive.
Statistical analysis
Wilcoxon Rank Sum Test was used to compare the
results of the antigen test using the two assays
described. Chi-square test was used to compare the
proportions between the old and the second-
generation assay.Results
To compare the second-generation assay with the
original enzyme immunoassay, BAL specimens from
19 patients with histoplasmosis, 6 cases of blas-
tomycosis and 54 controls were tested in both
assays simultaneously. Among the histoplasmosis
cases, antigen was detected in 16 out of 19 (84%) in
the second-generation assay vs. 13 of 19 (68%) in
the original assay. The second-generation assay was
positive in 5 of the 6 (83%) patients with blastomy-
cosis compared to 4 of the 6 (66%) in the original
assay (Fig. 1). Thus, overall BAL from 21 of 25 (84%)
histoplasmosis or blastomycosis patients werepositive in the second-generation assay compared
to 17 of 25 (64%) in the original assay (P ¼ 0:125,
Chi-square). Additionally, antigen levels were high-
er in the second generation EIA for both histoplas-
mosis (Po0:02) and blastomycosis (Po0:032).
Among the 54 controls, results were positive in a
single specimen (1.8%) in both assays, and it was
included because of elevated levels of A. galacto-
mannan. The Histoplasma antigen test was nega-
tive on four other specimens containing elevated
levels of A. galactomannan. To further assess
potential cross reactivity with A. galactomannan,
24 additional BAL specimens that were positive in
the Platelia assay were tested in the Histoplasma
antigen assay, of which none were positive.
Ten-fold concentration was performed on 16 BAL
ﬂuid samples (histoplasmosis, n ¼ 5; blastomycosis,
n ¼ 2; and non-fungal controls, n ¼ 9). The addi-
tion of a concentration step yielded positive
results in two false-negative specimens, one with
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centrated, 1.85 units) and another with blastomy-
cosis (unconcentrated, 0.72; concentrated, 4.96
units). These two specimens were not tested in the
original assay. Antigen levels signiﬁcantly increased
with concentration in two other cases in which the
unconcentrated specimens were positive (3.32 vs.
19.7 units, and 36.85 vs. 53.87 units). Concentra-
tion did not increase antigen levels in 9 antigen-
negative control specimens. With concentration, 23
of 25 (92%) specimens were positive in the second-
generation assay.Discussion
In this report, we have demonstrated the diagnostic
utility of Histoplasma antigen testing in BAL ﬂuid
for histoplasmosis and blastomycosis. The second-
generation Histoplasma antigen assay showed a
trend toward increased sensitivity in the BAL when
compared to the original EIA (84% vs. 68%), for both
histoplasmosis and blastomycosis. Although the
difference in sensitivity was not statistically sig-
niﬁcant, the second-generation test yielded higher
antigen levels in all but one of the 25 specimens
tested, suggesting that the lack of statistical
signiﬁcance is due to the small sample size.
Sensitivity was further improved to 92% by con-
centration of BAL specimens before testing. We
estimate that a sample size of at least 30 of each
disease will be necessary to reach statistical
signiﬁcance, and a prospective study is in progress
to expand the sample size and determine the
sensitivity in the different pulmonary syndromes.
We have previously reported the utility of
antigen detection for diagnosis of blastomycosis.9
The antigen detected in histoplasmosis,5 and
blastomycosis9 EIA is a cross-reactive polysacchar-
ide.10 Although the current assays are unable to
distinguish the two mycoses, a speciﬁc diagnosis
can usually be made by histopathology or culture,
or on clinical and epidemiological differences. Even
if the two mycoses cannot be differentiated,
antigen detection provides a basis for early treat-
ment, which is the same in blastomycosis and
histoplasmosis. The importance of rapid diagnosis is
emphasized by the often fatal outcome in patients
with pulmonary blastomycosis, highlighted in a
recent report of death in four children with
blastomycosis.11 Testing BAL may improve the
sensitivity of antigen detection for diagnosis of
pulmonary blastomycosis.
False-positive results were observed in 1.8% of
BAL specimens from controls, a specimen contain-
ing high levels of A. galactomannan. Additionaltesting found no false-positive results in specimens
containing A. galactomannan. Cross-reactions are
to be expected in specimens from patients with
paracoccidioidomycosis and penicillosis marnef-
fei.10 More recently, we have detected a cross-
reactive antigen in the urine from patients with
severe coccidioidomycosis (Wheat, unpublished
observation, 2006). These ﬁndings provide a basis
for the hypothesis that antigen testing in BAL can
improve the sensitivity for diagnosis of pulmonary
histoplasmosis and blastomycosis.
Prospective studies are in progress to answer
several important questions not addressed ade-
quately in this preliminary investigation. First,
what is the relative sensitivity of antigen detection
compared to cytology and histopathology? In an
earlier report, the sensitivity was 70% for antigen
detection and histopathology.4 In the current study,
histopathology was not available for specimens
submitted for clinical testing. Second, what is the
relative sensitivity of antigen detection in BAL
compared to urine and serum? The number of cases
with concurrent specimens was inadequate for that
analysis. Third, what is the sensitivity for diagnosis
of the different pulmonary syndromes? In the
earlier study, all patients had AIDS complicated by
disseminated histoplasmosis. In the current study,
the type of pulmonary infection was unknown for
the cases that were included based upon results of
antigen testing. Fourth, the speciﬁcity of the
antigen test requires further evaluation, since only
16 patients with other fungal diseases were
studied. Finally, the utility of concentration of the
BAL before testing requires further evaluation, as
there were too few false-negative specimens with
sufﬁcient volume to study following concentration.
In summary, the second-generation Histoplasma
antigen test has improved sensitivity for the
diagnosis of histoplasmosis and blastomycosis.
Although important questions remain to be an-
swered through a prospective study, these pre-
liminary ﬁndings support the utility of antigen
testing as an adjunct to histopathology and
cytology for evaluation of BAL in patients suspected
to have pulmonary histoplasmosis or blastomycosis.References
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